| 000 | 01788 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515092425.0 | ||
| 264 | 0 | _c20080408 | |
| 008 | 200804s 0 0 eng d | ||
| 022 | _a1478-6362 | ||
| 024 | 7 |
_a10.1186/ar2315 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKrzeski, Piotr | |
| 245 | 0 | 0 |
_aDevelopment of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. _h[electronic resource] |
| 260 |
_bArthritis research & therapy _c2007 |
||
| 300 |
_aR109 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxamic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMatrix Metalloproteinase Inhibitors |
| 650 | 0 | 4 |
_aMatrix Metalloproteinases _xmetabolism |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMusculoskeletal Diseases _xchemically induced |
| 650 | 0 | 4 |
_aOsteoarthritis, Knee _xdrug therapy |
| 650 | 0 | 4 |
_aProtease Inhibitors _xadministration & dosage |
| 700 | 1 | _aBuckland-Wright, Chris | |
| 700 | 1 | _aBálint, Géza | |
| 700 | 1 | _aCline, Gary A | |
| 700 | 1 | _aStoner, Karen | |
| 700 | 1 | _aLyon, Robert | |
| 700 | 1 | _aBeary, John | |
| 700 | 1 | _aAronstein, William S | |
| 700 | 1 | _aSpector, Tim D | |
| 773 | 0 |
_tArthritis research & therapy _gvol. 9 _gno. 5 _gp. R109 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/ar2315 _zAvailable from publisher's website |
| 999 |
_c17478379 _d17478379 |
||